[Show abstract] [Hide abstract]
ABSTRACT: The GlyT1 transporter has emerged as a key novel target for the treatment of schizophrenia. Herein, we report on the optimization of the 2-alkoxy-5-methylsulfonebenzoylpiperazine class of GlyT1 inhibitors to improve hERG channel selectivity and brain penetration. This effort culminated in the discovery of compound 10a (RG1678), the first potent and selective GlyT1 inhibitor to have a beneficial effect in schizophrenic patients in a phase II clinical trial.
Journal of Medicinal Chemistry 06/2010; 53(12):4603-14. DOI:10.1021/jm100210p · 5.45 Impact Factor